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Abstract
Molecular pharming is a cost-effective, scalable, and safe system to produce 
high-quality and biologically active recombinant therapeutic proteins. Thus, plants 
are emerging alternative platform for the production of pharmaceutically relevant 
proteins such as vaccines, antibodies, antibody derivatives, and some serum-
derived proteins. Additionally, plants have also been used to produce bioactive 
and immunogenic peptides. The efficacy, selectivity, specificity, and low toxicity 
make them particularly well-suited therapeutic agents for various indications, for 
instance, cardiovascular and infectious diseases, immunological disorders, and 
cancer. In the broad range of known bioactive peptides, angiotensin I-converting 
enzyme inhibitory (ACEI) peptides derived from food proteins have attracted 
particular attention for their ability to prevent hypertension. So far, several ACEI 
peptides have been identified in food proteins, mainly in milk, eggs, and plants. 
The industrial production of ACEI peptides is based on enzymatic proteolysis of 
whole food proteins, which leads to the release of small bioactive peptides with 
ACE-inhibitory activity. The problems associated to such procedures, namely, cost 
and loss of functional properties, have demonstrated the need to develop more 
straightforward methods to produce ACEI peptides. One viable hypothesis, dis-
cussed in this chapter, is to genetically engineer crop plants to produce and deliver 
antihypertensive peptides.
Keywords: plant engineering, recombinant protein, bioactive peptides,  
angiotensin I-converting enzyme, ACEI peptides
1. Introduction
The term “molecular pharming,” blend of pharmaceutical and farming, surfaced 
in the literature in the 1980s to refer to the production of high-value compounds in 
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transgenic animals. Nowadays, the expression is mainly employed to the production of 
recombinant pharmaceutically relevant proteins or secondary products in plants [1–3].
The roots of molecular pharming can be traced back to the mid-1980s when 
plants started to be genetically engineered to act as bioreactors that produced 
pharmaceutically relevant proteins. Barta et al. [4] demonstrated that tobacco and 
sunflower callus tissues were capable of expressing transcripts of a human growth 
hormone fusion gene. Although no protein was detected, this was the first report of 
plants expressing human genes and established plants as a potential production sys-
tem for recombinant therapeutic proteins. Later on, the expression of a full-sized 
IgG in tobacco [5] was a major breakthrough since it revealed the ability of plants 
to produce complex functional mammalian proteins of pharmaceutical relevance. 
In 1990, the “authenticity” of plant-derived recombinant proteins was proved 
even further with the production of the first human protein (serum albumin) with 
confirmed native structure in tobacco and potato [6].
After several studies that demonstrated the capacity of various plant species and 
systems to produce recombinant pharmaceutical proteins and peptides, during the 
1990s, the field of molecular pharming gained support and interest from the plant 
biotechnology community. The scientific attention was followed by commercial inter-
est, with many start-up companies being created to capitalize the advantages of plants 
in relation to the established platforms. These advantages include being a more cost-
effective, scalable, and safer means of producing pharmaceutically relevant proteins 
and peptides. In opposition to the fermentation-based traditional platforms that require 
a massive investment in bioreactors, plant-based production systems can be established 
with minimal investment and offer a myriad of different hosts and platforms [7]. 
However, the expectation that plants could easily compete for the market share of some 
well-established biopharmaceutical platforms, such as Chinese hamster ovary (CHO) 
cells, and that they could motivate the mainstream pharmaceutical industry to switch 
platforms was overinflated. The CHO epithelial cell lines are the most commonly used 
mammalian hosts for industrial production of therapeutic recombinant proteins. The 
technical limitations of plants, especially their lower yields compared to mammalian 
cell lines, allied to the colossal existing investment in fermentation infrastructures, the 
unfavorable public opinion on OGMs, and regulatory uncertainty, lead the mainstream 
pharmaceutical industry to be cautious and to a consequent stagnation of the molecular 
pharming field in the 2000s [8, 9]. This situation induced a change of paradigm con-
cerning molecular pharming: the initial vision of a highly scalable and low-cost produc-
tion system, while still valid, was replaced by the idea of a production system for certain 
niche products that are not easily manufactured by conventional systems [8, 9].
Molecular pharming embraces several platforms and technologies with different 
advantages and limitations, related by their use of plant tissues. Conversely to conven-
tional biopharmaceutical production systems that are based on few selected platforms, 
particularly the bacterium Escherichia coli, yeasts such as Pichia pastoris, and mamma-
lian cell lines such as Chinese hamster ovary (CHO) cells [3], pharming platforms range 
from plant cells or unicellular plants growing in bioreactors to whole plants growing in 
soil or hydroponic environments. Further, the technologies include stable integration of 
DNA into the nuclear genome or plastid genome and transient expression by infiltrat-
ing leaves with expression vectors based on Agrobacterium tumefaciens, plant viruses, 
or hybrids [3, 8]. This great diversity of molecular pharming confers adaptability and 
flexibility, allowing the selection of the most suitable platform for each product, but 
has also conduced to fragmentation. This fragmentation meant that in the early days 
of molecular pharming there was no driving force to establish molecular pharming as a 
single competitive platform. Consequently, no actions were made to match the indus-
try requirements for high yields, standardized procedures, and good manufacturing 
practices (GMP) [7, 9]. More recently, efforts have been made to mimic the mainstream 
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biopharmaceutical industry and place a focus only on a small number of platforms, 
namely, plant cell cultures, nuclear transgenic plants, and leafy plants transiently 
transformed [3, 10]. Since 2010 the attention of the biopharmaceutical industry to 
molecular pharming has been renewed as result of its consolidation on a small number 
of platforms and some target products that meet industry demands [8, 9].
In 2012, the FDA approval of the first recombinant plant-derived therapeutic for 
human use, Protalix Biotherapeutics’ taliglucerase alfa (Elelyso™), was an important 
breakthrough for molecular pharming. The enzyme taliglucerase alfa is a carrot cell-
expressed human recombinant β-glucocerebrosidase and is prescribed for the treatment 
of Gaucher’s disease, a lysosomal storage disorder [11]. Imiglucerase, a recombinant 
form of glucocerebrosidase commercialized under the name Cerezyme®, was already 
produced in CHO cells. In this production platform, the enzyme required subsequent 
in vitro exposure to mannose residues in order to have biological activity, resulting in 
a time-consuming and expensive manufacturing process. Besides, this platform also 
has potential safety problems, namely, the risk of viral contamination, allergies, and 
other adverse reactions. In comparison, the plant-based platform is safer and less time-
consuming and has reduced production costs, since the mannose units are posttransla-
tionally added in vivo [11]. Glucocerebrosidase is a clear example of a target product in 
which safety, cost, and downstream processing issues were solved by switching from a 
traditional platform to molecular pharming. Another example that gathered mediatic 
exposure was ZMapp, a cocktail of three chimeric monoclonal antibodies targeting the 
Ebola virus surface glycoprotein produced in Nicotiana benthamiana using a hybrid 
transient expression system, the magnICON system. ZMapp was developed during the 
Ebola outbreak of 2014 by Mapp Biopharmaceutical Inc. (San Diego, USA), following 
initial studies on nonhuman primates [12]. ZMapp has since been used in humans 
under emergency compassionate protocols [13] and randomized controlled trials [14].
Following these examples of success, there has been a continuous increase in 
clinical trial applications and manufacturing capacity, which has also been cor-
related with the conception of more tangible regulations concerning plant-derived 
pharmaceuticals.
Although plants are still unlikely to substitute the established platforms [8], the 
recent promising developments in the field of molecular pharming demonstrate that 
glucocerebrosidase was not a lone case of success and that plant-based platforms 
could provide countless opportunities for the biopharmaceutical market. Plants 
combine the advantage of a full posttranslational modification potential with 
simple growth requirements and theoretically unlimited scalability in the case of 
field-grown whole plants. Plant-based platforms are versatile and allow the targeting 
of recombinant proteins and peptides produced to different organs or subcellular 
compartments, which provides an additional protection against proteolysis. Finally, 
plants are a safe host for therapeutic protein and peptide production since they do not 
harbor human or animal pathogens [15]. Therefore, instead of facing the red ocean of 
established pharmaceutical industries [16], molecular pharming is now evolving as 
a disruptive technology that creates its own marketplace by offering rapid drug devel-
opment and production, unparalleled scalability, unique quality attributes such as 
tailored glycan structures, individualized therapies, and oral or topical applications 
of minimally processed plant tissues, thus reducing downstream costs [17].
2.  Plant platforms for the production of therapeutic proteins and 
peptides
The continuous development of genetic engineering technologies for plants has 
resulted in an expansion of well-established plant-based platforms [18]. Molecular 
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pharming encompasses platforms based on stably transformed whole-plants trans-
gene insertion in the nuclear or plastid genome, transient expression using agroin-
filtration, viral and hybrid vectors; microalgae and aquatic plants (e.g., duck-weed) 
stably transformed; and in vitro culture systems (e.g., cell suspensions, hairy roots, 
and moss protonema) [19]. Each platform has particular advantages and limita-
tions; therefore its selection is done on a case-by-case basis, depending on economic 
considerations as well as on the product characteristics and intended use [20].
2.1 Platforms based on transgenic plants
Transgenic plants have been the most widely used platforms for recombinant 
protein production. To obtain stable transgenic lines, the gene encoding the desired 
protein is cloned into an expression construct, which generally includes a promoter 
and regulatory elements that ensure efficient RNA processing and protein synthesis 
[21]. This expression construct is then stably integrated into the plant nuclear genome, 
resulting in the stable inheritance of the transgene and expression of stable pharma-
ceutical proteins over generations [22]. Two major transformation strategies have been 
employed to insert expression constructs into the nuclear genome: Agrobacterium-
mediated transformation in dicotyledonous species (dicots) and particle bombard-
ment of DNA-coated gold or tungsten beads in monocotyledonous species (monocots) 
[3]. Transgenic plant lines offer several advantages as platforms for molecular 
pharming: they are suitable for long-term production of recombinant pharmaceuti-
cal proteins and are highly scalable, as each line can be used to produce seeds, which 
increase the number of plants in every generation. Ultimately, the production capacity 
of recombinant pharmaceutical proteins in transgenic plants is practically unlimited, 
as it only depends on the number of hectares available for the plant culture. The major 
drawbacks of transgenic plants are the long development and scale-up timescales, the 
unreliable production yields, and the potential spread of pharmaceutical crops in the 
environment and into the food chain by outcrossing and seed dispersal [3].
The development of simple transformation technologies has expanded the 
number of host plants available for molecular pharming. Currently, the major 
molecular pharming transgenic platforms are based on leafy crops, seeds, fruits, 
and vegetable crops. Leafy crops are benefic in terms of biomass yield and high 
soluble protein levels. Additionally, leaf harvesting does not need flowering and 
thus considerably reduces contamination through pollen or seed dispersal [23]. 
One disadvantage of leafy crops is that proteins are synthesized in an aqueous 
environment, which is more prone to protein degradation, resulting in lower 
production yields [24]. In fact, the mature leaves possess very large extra cytoplas-
mic vacuolar compartments containing various active proteolytic enzymes that 
are involved in the degradation of native and foreign proteins. This is particularly 
problematic in the case of therapeutic peptide production because short heter-
ologous peptides have an inherent instability in plant cells [25]. In addition to the 
protein instability, the harvested material has limited shelf life and needs to be 
processed immediately after harvest.
Tobacco has been the most widely used leafy crop for molecular pharming. The 
major advantages of using tobacco to express pharmaceutical proteins are its high 
biomass yield, well-established technology for gene transfer and expression, year-
round growth and harvesting, and the existence of large-scale infrastructure for 
processing [23]. However, the natural production of nicotine and other alkaloids in 
tobacco poses some safety issues in its use as a host system for heterologous protein 
production. Therefore, tobacco varieties with low nicotine and alkaloid levels have 
been produced to diminish the toxicity and overcome those safety issues. Recent 
studies have led to the approval of the first monoclonal antibody produced in 
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transgenic tobacco plants, in phase I clinical trial [26]. Additionally, a 2018 publica-
tion reported the stable expression of adalimumab (a monoclonal antibody against 
tumor necrosis factor-alpha (TNF-α)) in tobacco plants [27]. Other leafy crops 
commonly used in molecular pharming include alfalfa and clover [19].
As an alternative to leafy crops, plant seeds have proven to be versatile hosts 
for recombinant proteins of all types, including peptides or short and long 
polypeptides as well as complex, noncontiguous proteins like antibodies and 
other immunoglobulins [28]. The expression of proteins in seeds can overcome 
the shortcomings of leafy crops in terms of protein stability and storage. Seeds 
possess specialized storage compartments, such as protein bodies and vacuoles, 
which provide the appropriate biochemical environment for protein accumula-
tion, thus protecting the proteins expressed in seeds from proteolytic degradation 
[29]. Reports have demonstrated that antibodies expressed in seeds remain stable 
for at least 3 years at room temperature without detectable loss of activity [30]. 
Furthermore, the small size of most seeds permits to achieve a high recombinant 
protein concentration in a small volume, which facilitates extraction and down-
stream processing and reduces the costs of the overall manufacturing process 
[31]. One essential property of seeds is dormancy, which not only permits the 
stability of recombinant proteins but also allows a complete decoupling of the 
cycle of cultivation from the processing and purification of the protein [28]. 
Finally, proteins expressed in the seed do not normally interfere with vegetative 
plant growth, and this strategy also reduces exposure to herbivores and other 
nontarget organisms such as microbes in the biosphere [21]. Several crops have 
been studied for seed-based production, including cereals, such as maize, rice, 
barley, and wheat; legumes, such as pea and soybean; and oilseeds such as saf-
flower and rapeseed. Maize has several advantages for seed-based expression 
of proteins; it has the highest biomass yield among food crops, and it is easy 
to transform, in vitro manipulate, and scale up [24]. These potentialities were 
explored by Prodigene Inc. for the production of the first commercially available 
plant-made protein, avidin (a protein with affinity for biotin used in biochemical 
assays). Other maize-derived protein products developed by this company include 
β-glucuronidase, aprotinin, laccase, and trypsin [32]. Prodigene was the first com-
pany to demonstrate the commercial benefits of plant-based platforms and was 
also a forerunner in the study of the economic impact of downstream processing 
in molecular pharming, having developed several successful approaches to recover 
intact and functional recombinant seeds from maize [3].
Maize has also been used to produce recombinant pharmaceutical proteins, 
including enzymes, vaccines, and antibodies [32, 33]. One of the most notable 
therapeutic proteins produced in maize is Meristem Therapeutics’ gastric lipase, an 
enzyme intended for the treatment of exocrine pancreatic insufficiency—a disease 
significantly affecting cystic fibrosis sufferers—that has completed phase II clinical 
trial. In addition to this enzyme, Meristem Therapeutics has developed two other 
maize-derived products, human lactoferrin (phase I clinical trial), whose intellec-
tual property was later acquired by Ventria Bioscience (http://www.ventria.com/), 
and collagen (pre-clinical stage).
Rice is another leading platform for recombinant protein and peptide produc-
tion. Similar to maize, rice is easy to transform and scale up, but unlike maize, rice is 
self-pollinating, which reduces the risk of horizontal gene flow. Ventria Bioscience, 
in its ExpressTec platform, has used rice to produce recombinant pharmaceutical 
proteins, including human albumin, transferrin, lactoferrin, lysozyme, and vaccines 
against human rabies and Lyme disease. Its lead therapeutic candidate VEN100, 
whose active ingredient is lactoferrin, has been shown to reduce significantly 
antibiotic-associated diarrhea in high-risk patients and recently completed phase 
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II clinical trial [34]. Rice has also been widely used as host for peptide expression, 
especially for the production of allergen peptides (e.g., pollen and mite allergies) 
[35, 36]. Recent studies report that rice has the potential to offer an oral delivery 
system for vaccine antigens and therapeutic proteins and peptides [25, 35, 37].
Barley seeds have also been developed as commercial platforms. In comparison 
to other cereal crops, barley is less widely grown. However, this fact added to the 
self-pollinating nature of barley can be viewed as an advantage since the risk of con-
tamination and outcrossing with non-transgenic crops is minimized. Considering 
this benefit, an Iceland-based company, ORF Genetics (https://orfgenetics.com/),  
has targeted barley grain as the expression host for several human cytokines 
and growth factors [19]. Other molecular pharming companies, such as Ventria 
Bioscience and Maltagen, have also been developing barley-based production 
platforms. Although barley is still recognized for its recalcitrance to transformation, 
over the last decade some progress has been made in the development of reliable 
transformation procedures [38].
The use of legume seeds, such as soybean and pea, for the production of 
recombinant pharmaceutical proteins, has been less explored than cereal-based 
platforms, with platforms based on legume seeds having yet to achieve commer-
cial success. However, the fact that legume seeds have exceptionally high protein 
content (20–40%) can be exploited to achieve high yields of recombinant protein 
[39]. Soybean seeds have been used to express recombinant growth factors [40, 41], 
coagulation factors [42], and vaccine peptides [43]. Transgenic pea seeds have been 
previously used to produce a single-chain Fv fragment (scFV) antibody used in 
cancer diagnosis and therapy [44]. In another study, pea seeds were used to produce 
a vaccine that showed high immunogenicity and protection against rabbit hemor-
rhagic disease virus [45].
Safflower and rapeseed seeds are rich in oil and are, thus, referred as oilseeds. 
Oilseeds can provide useful recombinant pharmaceutical protein production 
systems. SemBioSys (http://www.sembiosys.ca/), with its oleosin-fusion platform, 
has been a pioneer in that field. Oleosins are the principal membrane proteins of 
oil bodies; oleosins confer peculiar structural properties to the oil bodies that offer 
simple extraction and purification procedures [46]. In the oleosin-fusion platform 
the recombinant protein is fused with oleosin and consequently targeted to the oil 
bodies. The fusion protein is then recovered through simple purification of the oil 
bodies and separated from oleosin by endoprotease digestion. Commercial produc-
tion of hirudin in safflower by SemBioSys constituted the first report of an oilseed-
derived protein [47]. The company has been focusing on safflower as its primary 
host ever since, with safflower-derived insulin being in phase I clinical trial [32].
Finally, fruit and vegetable crops can also be employed for molecular pharm-
ing. A major advantage of protein expression in fruit and vegetable crops is that 
edible organs can be consumed uncooked, unprocessed, or partially processed, 
making them particularly suitable for the production of recombinant subunit 
vaccines, nutraceuticals, and antibodies designed for topical application [29]. The 
oral delivery of recombinant therapeutics is one of the differentiating factor of 
molecular pharming in comparison to mainstream biopharmaceutical production 
systems, with several pharmaceutical products being produced in tomato fruits, 
potato tubers, and lettuce leaves for this purpose [3]. Tomato fruits are particularly 
useful for protein expression because the fruits are palatable as raw tissue but can 
also be lyophilized and stored for a long time [25]. Recently, human coagulation 
factor IX (hFIX) was expressed specifically in tomato fruits, constituting the first 
report on the expression of hFIX in plant [48]. Another study described the expres-
sion in tomato fruits of a thymosin α1 concatemer [49], an immune booster that 
plays an important role in the maturation, differentiation, and function of T cells. 
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The thymosin α1 concatemer derived from transgenic tomatoes exhibited biological 
activity and was proven to stimulate the proliferation of mice splenic lymphocytes 
in vitro. Moreover, thymosin α1 specific activity was higher when produced in 
tomato than in Escherichia coli, demonstrating the authenticity of the plant-made 
product. Other examples of tomato fruit expression include F1-V [50], a candidate 
subunit vaccine against pneumonic and bubonic plague, and β-secretase [51], to 
serve as a vaccine antigen against Alzheimer’s disease.
In conclusion, platforms based on transgenic plants are a promising alternative 
to the conventional biopharmaceutical production platforms since they provide 
a stable source of pharmaceutical proteins and are also the most scalable of all 
molecular pharming platforms. This scalability of transgenic plants ensures the pro-
duction of recombinant pharmaceutical proteins at levels previously inaccessible, 
namely, the commodity bulk production of monoclonal antibodies. In the current 
scenario of growing pharmaceutical demand, especially in developing countries, 
the use of transgenic plants can be game changing since they provide a highly scal-
able and low-cost means of producing medicines.
2.2 Platforms based on transplastomic plants
Transplastomic plants are a valuable alternative to transgenic plants for the 
production of recombinant pharmaceutical proteins. Transplastomic plants are 
obtained by the insertion of expression constructs into the plastid genome by 
particle bombardment. Since the Agrobacterium T-DNA (transfer DNA) complex 
is targeted to the nucleus, it is unsuitable for gene transfer to chloroplasts [24, 52]. 
Following the transformation procedure, the bombarded leaf explants are regener-
ated, and transplastomic plants with homoplastomic transformation (in which 
every chloroplast carries the transgene) are finally selected, recurring to a selection 
medium containing spectinomycin or in combination with streptomycin [53].
Plastid transformation can result in high yields of heterologous proteins because 
multiple copies of the genome are present in each plastid, and photosynthetic cells 
may contain hundreds or thousands of plastids [54]. As an example, the expression 
of a proteinaceous antibiotic in tobacco chloroplasts has achieved up to 70% of 
the total soluble proteins, which is the highest recombinant protein accumulation 
accomplished so far in plants [55]. Furthermore, chloroplasts provide a natural 
biocontainment of transgene flow since genes in chloroplast genomes are mater-
nally inherited and consequently not transmitted through pollen, thereby avoiding 
unwanted escape into the environment. Other advantages of chloroplast engineer-
ing include the ability to express several genes as operons, and the accumulation of 
recombinant proteins in the chloroplast, thus reducing toxicity to the host plant [24].
Finally, transplastomic production platforms offer the possibility of oral delivery 
[54, 56]. In fact, it has been demonstrated that chloroplast-derived therapeutic 
proteins, delivered orally via plant cells, are protected from degradation in the 
stomach, probably due to the bioencapsulation of the therapeutic protein by the 
plant cell wall. They are subsequently released into the gut lumen by microbes that 
digest the plant cell wall, where the large mucosal intestine area offers an ideal 
system for oral drug delivery [57].
A shortcoming of expressing proteins via the chloroplast genome is that routine 
plastid engineering is still limited to tobacco, a crop that is not edible and thus 
unsuitable for oral delivery of therapeutic proteins. In addition, the synthesis of gly-
coproteins is not possible in the chloroplast system, as plastids do not carry out gly-
cosylation [24]. Nevertheless, the expression of human somatotropin [58] in tobacco 
established that chloroplasts are capable of properly folding human proteins with 
disulfide bonds. In another study, the production of native cholera toxin B subunit 
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[59] demonstrated the capacity of chloroplasts to fold and assemble oligomeric 
proteins correctly. Other therapeutic proteins expressed in tobacco chloroplasts 
include interferons alpha-2a and alpha-2b [60, 61] and anti-cancer therapeutic agents 
such as human soluble tumor necrosis factor (TNF) [62] and azurin [63]. Recently, 
chloroplast transformation of lettuce has also been developed [64, 65] to provide oral 
delivery transplastomic systems [66, 67]. Several therapeutic proteins were produced 
in lettuce chloroplast, namely, proinsulin [66, 67], tuberculosis vaccine antigens 
[68], and human thioredoxin 1 protein [69]. The chloroplast production platform 
has yet to achieve commercial success, though the referred developments in this field 
augur a promising future for therapeutic protein production in chloroplasts.
2.3 Transient expression platforms
Transient expression is a phenomenon that occurs when genes are introduced 
into plant tissues and are expressed for a short period without stable DNA integra-
tion into the genome [3]. Traditionally, transient expression was used to verify 
expression construct activity and to test recombinant protein stability. This strategy 
allowed the identification and elimination of initial transformation problems, and 
thus the prospect of regenerating the desired transgenic lines was significantly 
improved. Recently, there has been an emergence of transient expression for the 
commercial production of recombinant pharmaceutical proteins. The advantages 
of transient expression platforms include the ease of manipulation, speed, low cost, 
and high yield of proteins. In comparison to transgenic plants, transient expression 
permits to achieve higher recombinant protein yields because there are no position 
effects (suppression of transgene expression by the surrounding genomic DNA 
following integration) [70].
Transient expression systems utilize the beneficial properties of plant pathogens 
to infect plants, spread systemically, and express transgenes at high levels, causing 
the rapid accumulation of recombinant proteins [8]. Currently, the major transient 
expression platforms are based on Agrobacterium tumefaciens, plant viruses, or 
hybrid vectors that utilize components of both (magnICON® technology).
The agroinfiltration method involves the vacuum infiltration of a suspension of 
recombinant A. tumefaciens into the plant leaf tissue, with the transgenes being then 
expressed from the uninterrupted T-DNA [8, 71]. Using this method, milligram 
amounts of recombinant protein are produced within a few weeks without the need 
to select transgenic plants, a process that takes months to years to be completed. 
This system has been commercially developed in tobacco [72] and alfalfa [73] but is 
also applicable to other crops such as lettuce [74], potato [75], and Arabidopsis [76]. 
An advantage of Agrobacterium-mediated transient expression is the fact that it 
allows to produce in plants complex proteins assembled from subunits [70].
Another transient expression technology is based on the use of plant viruses. In 
this technology, the gene of interest is inserted among viral replicating elements, 
episomically amplified and subsequently translated in the plant cell cytosol [77]. 
To date, the most efficient and high-yielding platforms have been developed using 
RNA viruses [78]. These plant viruses include Tobacco mosaic virus (TMV), potato 
virus X (PVX), and Cowpea mosaic virus (CPMV) (reviewed in [8]). The advantages 
of virus-based production include the rapid recombinant protein expression, the 
systemic spread of the virus, and the fact that multimeric proteins such as antibod-
ies can also be produced by coinfecting plants with noncompeting vectors derived 
from different viruses [79, 80]. Transient expression vectors based on virus have 
been used to express peptides and long polypeptides (at least 140 amino acids long) 
as fusions to the coat protein, resulting in the assembly of chimeric virus particles 
(CVPs) displaying multiple copies of the peptide or polypeptide on its surface [77, 81].  
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Transient expression based in plant viruses has been commercially adopted by the 
now-closed Large Scale Biology Corporation (Vacaville, USA) that used a TMV-
based vector for the production of patient-specific idiotype vaccines for the treat-
ment of B-cell non-Hodgkin’s lymphoma, which had successfully passed the phase I 
clinical trials [82].
Finally, the third transient expression strategy is based on hybrid systems that 
incorporate components of the T-DNA transfer and virus replication systems [3]. 
These hybrid systems use deconstructed viruses obtained by removing the coat 
protein (responsible for systemic movement) of the noncompeting virus strains 
and use Agrobacterium as the vehicle for the systemic delivery of the resulting viral 
vectors to the entire plant. These systems effectively address most of the major 
shortcomings of earlier plant-based technologies by providing the overall best 
combination of the following features: high expression level, high relative yield, low 
up- and downstream costs, very fast and low-cost R&D, and low biosafety concerns 
[83]. Consequently, there has been a commercial development based on several 
hybrid systems. One of most notable examples is the magnICON® system developed 
by Icon Genetics (https://www.icongenetics.com/) (formerly owned by Bayer 
Innovation, Dusseldorf, Germany; now a subsidiary of Nomad Bioscience, Halle, 
Germany), which features a deconstructed Tobacco mosaic virus (TMV) genome and 
A. tumefaciens as a delivery vehicle [83]. Another example is the iBioLaunch plat-
form developed by the Fraunhofer Center for Molecular Biotechnology, which also 
features a deconstructed TMV genome [3]. Finally, the CPMV-HT platform is based 
on a deleted version of Cowpea mosaic virus RNA-2 and also allows the “hypertrans-
lation” of recombinant proteins without virus spreading [8].
Examples of therapeutic recombinant proteins produced in these platforms have 
been generally reviewed in [3]. Recombinant protein production using transient 
expression is now being mobilized to a large scale with several companies develop-
ing scalable, automated plant-based GMP biomanufacturing facilities to efficiently 
produce large amounts of pharmaceuticals within weeks. Such facilities include the 
ones of the Fraunhofer Center for Molecular Biotechnology (Newark, DE) (https://
www.fraunhofer.org/), Medicago Inc. (Quebec, Canada) (http://www.medicago.
com/), Icon Genetics (Bayer; Halle, Germany) (http://www.icongenetics.com/), 
Texas A & M (College Station, TX), and Kentucky BioProcessing LLC (Owensboro, 
KY) (http://www.kbpllc.com/) [19].
In conclusion, the ability of transient plant expression systems to produce large 
quantities of recombinant protein, coupled to the use of current technology to 
increase yields, and the many promising technical solutions seems to be favorable 
compared with mammalian- or insect cell-based systems in quality, cost, and scale 
[19]. In case of emerging threats, transient platforms are advantageous since they 
produce large amounts of recombinant proteins rapidly (milligram quantities per 
plant within a few days) and can be scaled up quickly, currently providing the only 
reliable platform for rapid response situations [9]. During the H1N1 pandemic, the 
first batches of H1N1 virus-like particles (VLPs) could be produced by Medicago 
Inc. as soon as 3 weeks after the Centers for Disease Control and Prevention 
released the new influenza hemagglutinin sequence [73]. Similar lead times were 
reported for the H5N1 VLP vaccine [84]. Recently, the application of tobacco plant-
based transient production systems, at Kentucky BioProcessing (KBP), to produce 
antibody lots against Ebola, was shown to significantly decrease the amount of time 
required for production over traditional methods, increase the quantity of antibody 
produced, and reduce the cost of manufacturing. Finally, at the other end of the 
market scale, transient expression platforms are economical for the production of 
pharmaceuticals for very small markets, such as orphan diseases and individualized 
therapies.
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2.4 Callus and plant cell suspension cultures
Plant cell suspension cultures grow as individual cells or small aggregates and 
are usually derived from callus tissue by the disaggregation of friable callus pieces in 
shake bottles and are later scaled up for bioreactor-based production. Recombinant 
pharmaceutical protein production is achieved using transgenic explants to derive 
the cultures or by transforming the cells after disaggregation, usually by co-cultiva-
tion with A. tumefaciens. The co-cultivation of plant cell suspensions and recombi-
nant A. tumefaciens has also been used for the transient expression of proteins [85]. 
Since these plant cell suspension cultures are grown in sterile contained environ-
ments, they provide a cGMP-compatible production environment that is more accept-
able to the established pharmaceutical industry and regulatory authorities [3, 86].  
These systems have added benefits of complex protein processing compared to 
bacteria and yeasts and increased safety compared to mammalian cell systems, which 
can harbor human pathogens. Another advantage of plant suspension cultures is the 
very low maintenance cost in comparison to other fermenter-based eukaryotic sys-
tems such as mammalian or insect cells. Moreover, the possible secretion of the target 
protein into the culture medium simplifies downstream processing and purification 
procedures [87, 88]. Nevertheless, plant cell cultures also have some limitations such 
as poor growth rates, somaclonal variation (particularly due to chromosomal rear-
rangements, common in plant cell cultures generated by calli), and gene silencing, 
together with the inhibition of product formation at high cell densities, formation 
of aggregates, cell wall growth, as well as shear-sensitivity for some species [89]. 
However, high levels of functional recombinant protein in plant cell suspension 
cultures were already obtained [87]. Besides, the previously mentioned first licensed 
recombinant pharmaceutical protein, Elelyso™, was produced in plant cell suspen-
sion cultures (reviewed in [88]). Tobacco has been the most popular source of sus-
pension cells for recombinant protein production. Tobacco plants proliferate rapidly 
and are easy to transform, but other plant species have also been used to generate 
suspension cells, including rice and Arabidopsis thaliana, alfalfa, soybean, tomato, 
Medicago truncatula, and carrot [85, 88, 90]. Carrot suspension cells have been used 
by the aforementioned Protalix Biotherapeutics to produce a recombinant gluco-
cerebrosidase. This case of commercial success shows that suspension cell cultures 
have potential as a viable system for large-scale protein production. Recently, carrot 
callus cultures, expressing epitopes from the cholesteryl ester transfer protein, were 
accessed for the potential of becoming an atherosclerosis oral vaccine [91].
3. Optimization of plant expression levels
The lower expression levels in comparison to the established biopharmaceutical 
platforms were one of the major obstacles for the commercialization of molecular 
pharming [9]. Therefore, numerous techniques have been developed to enhance 
protein expression, including codon optimization of protein sequences, to match 
the preferences of the host plant, targeting subcellular compartments that allow 
proteins to accumulate in a stable form; the use of strong, tissue-specific promoters; 
and the testing of different plant species and systems [25].
Protein synthesis can be increased by optimizing the components of the expres-
sion construct to maximize transcription, mRNA stability, and translation or by 
diminishing the impact of epigenetic phenomena that inhibit gene expression [92]. 
In this field, the general strategy is to use strong and constitutive promoters, such as 
the cauliflower mosaic virus 35S RNA promoter (CaMV 35S) and maize ubiquitin-1 
promoter (ubi-1), for dicots and monocots, respectively. However, organ- and 
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tissue-specific promoters are also being used to drive expression of the transgenes 
to a specific tissue or organ such as the tuber, the seed, and the fruit. Additionally, 
inducible promoters, whose activities are regulated by either chemical or external 
stimulus, may equally be used to prevent the lethality problem. Furthermore, tran-
scription factors can also be used as boosters for the promoters to further enhance 
the expression level of the transgenes [53].
Protein stability can be increased by targeting proteins to cell compartments that 
reduce degradation. Protein targeting also affects the glycan structures added to 
proteins and the type of extraction and purification steps required to isolate the pro-
tein from the plant matrix. Proteins can be targeted to the secretory pathway by an 
N-terminal signal peptide, which is cleaved off for the release of the protein into the 
endoplasmic reticulum (ER). Proteins that do not require posttranslational modifi-
cation, e.g., glycosylation, for their activity, can be targeted to the chloroplast using 
N-terminal transit peptides [93]. In addition, the target gene can be used to trans-
form chloroplast directly, with highly enhanced protein accumulation. Moreover, 
posttranslational modifications of the ER lumen can also be avoided by expressing 
the protein as translational fusion with oleosin protein, which target the expression 
of the foreign protein to oil bodies of the seeds [28]. Other subcellular compartments 
like the protein-storing vacuoles are now being explored for recombinant protein 
accumulation, as it has been observed in rice seed endosperm [94].
4. Downstream processing
In the early years of molecular pharming, scientific studies were focused on dem-
onstrating that plants could produce adequate quantities of recombinant pharmaceu-
tical proteins and confer an oral delivery means. This led to downstream processing 
and the costs associated to it being basically overlooked. Downstream processing is 
now known to be an economically critical part of biomanufacturing processes (it 
can account for up to 80% of the total cost in a therapeutic protein production line) 
and also to be a key component of the regulatory process for evaluating the safety 
of pharmaceutical products [7]. The goal and the general steps for downstream 
processing are similar between plant and other expression systems: to recover the 
maximal amount of highly purified target protein with the minimal number of 
steps and at the lowest cost. The basic steps for downstream processes include tissue 
harvesting, protein extraction, purification, and formulation [22]. However, since 
in molecular pharming the costs of downstream processing are product-specific 
rather than platform-specific, the evaluation of downstream processing strategies 
and costs associated to it has to be done on a case-by-case basis. Nevertheless, even if 
unit operations have to be developed based on the properties of the product, others 
have to be developed based on the properties of the expression host. Plants produce 
process-related contaminants that require specific processing steps to ensure removal 
of fibers, oils, superabundant plant proteins such as RuBisCO, and potentially toxic 
metabolites such as the alkaloid nicotine in tobacco [8]. These secondary metabo-
lites can be recovered from plant cells or tissues using methods such as adsorption, 
precipitation, and chromatography, often requiring phase partitioning and the use 
of mixtures of organic solvents. Several approaches have been used to facilitate 
downstream processing, including secretion of recombinant proteins, eliminating 
the plant cell disruption step; targeting of proteins into the protein bodies, oil bodies, 
or plastoglobules; and the use of affinity tags such as poly-histidine tags with the 
target protein, allowing protein purification by affinity chromatography [25]. In 
addition, oral delivery of whole plants or crude extracts containing the pharmaceuti-
cal relevant proteins can also be a way to simplify downstream processing and to 
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easily distribute medicines to those in need. Furthermore, the optimization of plant’s 
expression level can also ease downstream processing, with higher protein concen-
trations conducting to higher protein volumes [7].
Finally, several purification strategies have been investigated to separate 
target transgenic proteins from host plant proteins, which are tailored for each 
individual protein based on its solubility, size, pI, charge, hydrophobicity, or 
affinity to specific ligands, and the parallel characteristics of plant host proteins. 
Chromatographic methods, such as affinity chromatography, have been the most 
extensively used. However, recently increasing attention is being paid to non-
chromatographic methods to provide alternatives for large-scale production [22].
5.  Heterologous production of bioactive angiotensin I-converting 
enzyme inhibitory (ACEI) peptides
In the broad range of known bioactive peptides, angiotensin I-converting 
enzyme inhibitory (ACEI) peptides derived from food proteins have attracted par-
ticular attention and have been studied the most comprehensively for their ability 
to prevent hypertension [95]. In this chapter we will further focus on the possibility 
to genetically engineer crop plants to produce and deliver antihypertensive ACEI 
peptides, therefore creating alternative sources to fight hypertension and prevent 
cardiovascular disease.
5.1 Cardiovascular disease and the renin-angiotensin system
Cardiovascular disease (CVD) has been recognized as the leading cause of death 
in developed countries. Hypertension or high blood pressure is one of the major 
independent risk factors for CVD [96]. States of CVD include conditions such as 
coronary heart disease, peripheral artery disease, and stroke. Hypertension is a 
condition defined by a blood pressure measurement of 140/90 mmHg or above and 
is thought to affect up to 30% of the worldwide adult population [95]. The kinin-
nitric oxide (KNO) system and the renin-angiotensin system (RAS), Figure 1, play a 
crucial role in the control of hypertension by the action of angiotensin I-converting 
key enzyme (EC 3.4.15.1; ACE) [96–99].
Several synthetic ACE inhibitors such as captopril, enalapril, and lisinopril have 
been prescribed for the treatment of hypertension, congestive heart failure, and 
diabetic neuropathy [100]. However, their consumption is associated with various 
side effects including cough, skin rashes, hypotension, loss of taste, angioedema, 
reduced renal function, and fetal abnormalities [95]. The side effects associated 
to synthetic ACE inhibitors and the high prevalence of hypertension have led 
scientists to search for natural and safer therapies. Interestingly, the study of ACEI 
peptides has revealed that they do not have significant effects on blood pressure in 
normotensive subjects, suggesting a convenient mechanism that avoids acute hypo-
tensive effects. Based on this finding, it is hypothesized that ACEI peptides could be 
used in initial treatment of mildly hypertensive individuals or even as supplemental 
treatments [101].
5.2 Antihypertensive ACEI peptides
So far, several ACEI peptides have been identified in food proteins, mainly 
in milk, eggs, and plants, currently constituting the most well-known class of 
bioactive peptides [102–104]. These peptides are inactive within the sequence 
of parent proteins, but they can be released by enzymatic proteolysis in vivo or 
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in vitro, for example, during gastrointestinal digestion or during food process-
ing. A common feature shared by the majority of ACEI peptides is the generally 
short sequence, i.e., 2–12 amino acids in length. However, some larger inhibitory 
sequences have been identified in milk fermented with Enterococcus faecalis [105] 
and Lactobacillus casei Shirota [106], in koumiss [107], tuna [108], bonito [109], 
and rotifer [110]. Studies have also indicated that binding to ACE is strongly 
influenced by the substrate’s C-terminal tripeptide sequence. Hydrophobic amino 
acid residues with aromatic or branched side chains at each of the C-terminal 
tripeptide positions are common features among potent inhibitors. The presence 
of hydrophobic Pro residues at one or more positions in the C-terminal tripeptide 
region seems to positively influence a peptide’s ACE-inhibitory activity [95]. In 
general, the peptides showing higher activity against ACE have Tyr, Phe, Trp, 
or Pro at their C-terminus [95]. The peptides TQVY from rice [111], MRW from 
spinach [112], and YKYY from wakame [113] are some examples of this principle. 
Table 1 reviews some examples of ACEI activities of plant origin, whose pep-
tides responsible for such activity may be potential sources for the heterologous 
production of ACEI peptides.
The most common method to produce and identify ACEI peptides is through 
enzymatic hydrolysis of food proteins with gastrointestinal enzymes such as pepsin 
and trypsin or with commercial proteases such as Alcalase™ [127]. ACEI peptides 
have also been produced with Lactobacillus, Lactococcus lactis, and E. faecalis strains 
during milk fermentation [105, 106]. Nevertheless, there are problems associated 
to this type of industrial production of ACEI peptides, including the difficulty to 
isolate the peptide of interest from the complex mixture of compounds produced by 
enzymatic hydrolysis, the high cost, low recovery, and the low bioavailability. These 
disadvantages denote the need to develop new and alternative approaches for their 
production.
Figure 1. 
The kinin-nitric oxide (KNO) system and the renin-angiotensin system (RAS). The left side (KNO system) 
shows the mechanism of the action of ACEI on ACE that cleaves bradykinin, a nonapeptide acting as 
vasodilatory hormone, and causes the formation of an inactive heptapeptide. In the right side (RAS system), 
the inhibition of ACE activity plays an important physiological role in regulation of blood pressure by 
inhibiting the conversion of the hormone angiotensin I to angiotensin II, a potent vasoconstrictor (figure 
adapted from Erdmann et al. [96]).
Genetic Engineering
14
5.3 Heterologous production of ACEI peptides in plants
In recent years, the application of recombinant DNA technologies for the 
production of ACEI peptides at a large scale and low cost has gathered attention in 
the biotechnology community. Investigation has been focused on the development 
of expression methods for antihypertensive peptide production in different plant 
crops [128]; and here, we tried to provide some promising examples.
Thus far, the main strategies that have been adopted are as follows: the over-
expression of ACEI peptide precursor proteins and the production of particular 
peptides as heterologous components [101], the modification of some storage 
proteins to produce chimeric proteins carrying ACEI peptides [101], and also the 
generation of multimer proteins containing tandem repeats of ACEI peptides, 
flanked by protease recognition sequences that allow the peptide release during 
gastrointestinal digestion.
5.3.1 Rice
Transgenic rice plants that accumulate novokinin (RPLKPW), a potent 
antihypertensive peptide designed according to the structure of ovokinin (2–7) 
(RADHPF), as a fusion with the rice storage protein glutelin, have been generated. 
The engineered peptide is expressed under the control of endosperm-specific glu-
telin promoters and specifically accumulates in seeds. Oral administration of either 
the RPLKPW-glutelin fraction or transgenic rice seeds to spontaneously hyperten-
sive rats (SHRs)—the main model for assessing the in vivo activity of ACEI peptides 
(e.g., [108, 111, 122])—significantly reduced systolic blood pressures, suggesting 
Source ACEI activity (IC50; μM) Antihypertensive activity 
(mmHg)
Dose (mg/kg) Reference
Chlorella vulgaris 29.6 Not determined — [114]
Chebulic myrobalan 100 Not determined — [115]
Bitter melon 8.64 −31.5 to −36.3 2–10 [116]
Mung bean 13.4 Not determined — [117]
Pea 64 Not determined — [118]
Peanut 72 Not determined — [100]
Potato 18–86* Not determined — [119]
Rapeseed 28 −11.3 7.5 [120]
Rice 18.2 −40 30 [111]
Soybean 14–39* −17.5 2 [121]
Soybean 21 Not determined — [122]
Soybean 1.69 Not determined — [123]
Soybean 17.2 Not determined — [124]
Spinach 0.6–4.2* −13.5 to −20* 20–100 [112]
Wakame 21–213* −50 50 [113]
Walnut 25.7 Not determined — [125]
Wheat 20 Not determined — [126]
*Different values for the same plant product related to the ACEI peptide sequence.
Table 1. 
Examples of ACEI peptide activity from different plant origin.
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the possible application of transgenic rice seed as a nutraceutical delivery system 
and particularly for administration of antihypertensive peptides [129].
Wakasa et al. [130] attempted the generation of transgenic rice seeds that would 
accumulate higher amounts of novokinin peptide by expressing 10 or 18 tandemly 
repeated novokinin sequences, with the KDEL endoplasmic reticulum retention 
signal at the C-terminus, and using the glutelin promoter along with its signal 
peptide. Although the chimeric protein was unexpectedly located in the nucleolus 
and the accumulation was low, a significant antihypertensive activity was detected 
after a single oral dose to SHRs. More importantly, this effect was observed over a 
relatively longer duration time, with intervals of 5 weeks between doses as low as 
0.0625 g transgenic seeds per kg.
5.3.2 Soybean
Soybean [Glycine max (L.) Merr.] is an attractive option for the production of 
ACEI peptides given that soybean seeds contain a large amount of total protein. 
Therefore, there has been an effort to generate soybean lines with improved ACEI 
properties foreseeing the creation of novel functional foods.
Matoba et al. [128], introduced novokinin (RPLKPW) into homologous 
sequences of a soybean β-conglycinin α’ subunit by site-directed mutagenesis. 
Founded on first achievements from an E. coli expressed protein, the muted 
β-conglycinin α’ subunit carrying novokinin repeats were also expressed in soy-
bean. This chimeric protein accumulated at levels of up to 0.2% of extracted protein 
from transgenic soybean seeds [131]. Still, the levels of expression were too low, and 
it was not possible to assess the in vivo effects of these soybean seeds.
Novokinin has also been expressed in transgenic soybean seeds in a fusion 
form along with a β-conglycinin α’ subunit. Interestingly, a reduced systolic blood 
pressure was observed in SHRs after administering a dose of 0.15 g kg−1 of protein 
extracts. A similar effect was attained following administration of a 0.25 g kg−1 dose 
of defatted flour. Thus, it was concluded that this chimeric protein produced in 
soybean possessed an antihypertensive activity [132].
Additionally, a synthetic gene of His-His-Leu (HHL), an ACEI peptide derived from 
a Korean soybean paste, was tandemly multimerized to a 40-mer, ligated with ubiquitin 
as a fusion gene (UH40), and subsequently expressed in E. coli. Following digestion 
with leucine aminopeptidase, the 405-Da HHL monomer was recovered by reverse-
phase high-performance liquid chromatography (HPLC). MALDITOF mass spectrom-
etry, glutamine-TOF mass spectrometry, N-terminal sequencing, and measurement of 
ACE-inhibiting activity confirmed that the resulting peptide was the HHL [133]. The 
potential use of this antihypertensive chimeric protein in soybean has yet to be assessed.
5.3.3 Tomato and tobacco
A modified version of amarantin, the main seed storage protein of Amaranthus 
hypochondriacus, carrying four tandem repeats of the ACEI dipeptide Val-Tyr 
into the acidic subunit of amarantin, was expressed in cell suspension cultures 
of Nicotiana tabacum L. NT1. Protein hydrolysates obtained from transgenic calli 
showed high levels of inhibition of the angiotensin-converting enzyme, with an 
IC50 value of 3.5 μg ml−1, and 10-fold lower levels than that of protein extracts of 
wild-type cells (IC50 of 29.0 μg ml−1) [134]. This was the first time that a chimeric 
protein comprising an ACEI peptide was produced in plant cell suspension cultures.
This modified version of amarantin was also expressed in the fruit of trans-
genic tomato plants. Protein hydrolysates from transgenic tomato fruits showed 
in vitro ACE inhibition, with IC50 values ranging from 0.376 to 3.241 μg ml−1; 
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this represented an increase of up to 13-fold in the inhibitory activity when 
compared with the protein hydrolysates of non-transformed fruits [135]. These 
two results suggest the possible application of tobacco plant cell suspension 
cultures and transgenic tomato fruits for massive production of this engineered 
version of amarantin, which could be especially used as an alternative hyperten-
sion therapy [134, 135].
5.3.4 Amaranth
Although amaranth has not been genetically modified to produce ACEI peptides, 
the feasibility of developing a modified amarantin acidic subunit has been widely 
assessed [129, 134–139]. Recently, the in vivo effect of an E. coli-modified amaran-
tin protein, four units of Val-Tyr dipeptides (VY) in tandem, and one of Ile-Pro-
Pro tripeptides (IPP) incorporated in the amarantin acidic subunit (AMC3) was 
evaluated in SHRs in a one-time oral administration experiment. This study showed 
that enzymatic hydrolysates of AMC3-containing ACEI peptide (4xVY and IPP) 
sequences had significant in vivo antihypertensive action [138]. The positive reports 
of amarantin expression in E. coli [136, 138, 139] along with the sustained expres-
sion of amarantin-modified proteins in tobacco [134] and tomato [135] prospect the 
successful production of ACEI peptide fusion proteins in amaranth.
Figure 2. 
Schematic representation of the technologies involved in different plant platforms for the production of 
therapeutically important proteins and peptides. Plastid transformation by particle bombardment can result 
in regeneration of transplastomic plants, revealing high-yield heterologous production, with the possibility 
of protein/peptide oral delivery or purification. Nuclear transformation can be accomplished by particle 
bombardment or by Agrobacterium-mediated transformation, resulting in the regeneration of stable transgenic 
plants. Finally, the technology based on transient expression, here with the example of agroinfiltration. We 
present Medicago truncatula and lettuce as examples: (a) M. truncatula co-culture of leaf explants with 
Agrobacterium, (b) and (c) plant regeneration via somatic embryogenesis according to Araújo et al. [145], (d) 
and (e) establishment of a cell suspension culture from callus for protein/peptide production [146, 147], (f) 
lettuce leaf explant co-culture with Agrobacterium, (g) and (h) plant regeneration via shoot organogenesis 
at PCB lab, (i) lettuce transgenic plants which can be used for oral delivery, (j) and (k) agroinfiltration of 
lettuce leaf explants according to Negrouk et al. [74], and (l) example of a control explant (left) and transient 
expression of a 35S::GUS(int) cassette in lettuce leaves (right).
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5.3.5 Lettuce and Medicago truncatula
Lettuce (Lactuca sativa) is a commercially important crop belonging to the 
Asteraceae family. It is a diploid (2n = 18), autogamous species with a genome size 
of 2.7 Gb [140]. This crop is particularly suitable for oral delivery of therapeutics 
as its raw leaves are consumed by humans, and the time to obtain an edible product 
is only weeks, compared to the months needed for crops such as tomato or potato. 
Therefore, recently lettuce has been investigated as a production host for edible 
recombinant therapeutics [66, 67, 141]. Furthermore, the fact that stable transfor-
mation procedures for both nuclear [142] and plastid genomes [64], and transient 
expression [74], are widely available, is also an advantage. Lettuce has been used as 
production host for several recombinant therapeutics, virus-like particles (VLPs) 
and monoclonal antibodies [143], antigens [142, 144], and human therapeutic 
proteins [66, 69].
Medicago truncatula is a model plant from the legume family. It is a diploid 
(2n = 16), autogamous species, with a relatively small genome and short life cycle of 
3–5 months. These characteristics enable this species to be used in molecular genetic 
studies and expression of foreign genes [145]. The phylogenetic distance to eco-
nomically important crops is crucial in the choice of this plant by many researchers 
and funding agencies, since it allows comparative studies within the legume family. 
The methodologies for the establishment of long-term cell suspension culture are 
well recognized [146], and the potential of M. truncatula as expression host has also 
been established for the production of feed additives [20, 87], human hormones 
[90], and human enzymes [147].
The use of these two species in molecular pharming is at the center of a recent 
collaboration between the Plant Cell Biotechnology (PCB) Laboratory (ITQB 
UNL), the Cell Differentiation and Regeneration Laboratory (iBiMED UA), and the 
Institute of Plant Genetics (IPG PAS). This cooperation foresees the usage of these 
two species as exceptional hosts for the heterologous production and/or delivery of 
ACEI peptides, and a resume of this ongoing project is here schematically presented 
(Figure 2). This figure also provides an overview of the technologies involved in 
different plant platforms discussed in this chapter.
6. Conclusions
Molecular pharming has been recently and extensively reviewed, and the future 
of this technology has gathered some optimistic expectations. A myriad of studies 
have already demonstrated the capacity of various plant species and systems to 
produce recombinant pharmaceutical proteins and peptides. This technology has 
already been put to the test in case of emerging threats, where transient platforms 
proved to be strategic for rapid production of large amounts of recombinant pro-
teins in response to pandemic situations. However, their usefulness for the produc-
tion of functional foods still falls short of expectations, as well as the attainment of 
its full potential in bioactive peptide production. With the improvement of known 
plant platforms and development of new genetic engineering techniques and their 
exploration, it is forthcoming an evolution in the production of heterologous bioac-
tive peptides, to which we hope to contribute with our ACEI pharming project. 
The advent of genome editing techniques (with the advantage of site- specific 
gene insertion), like the CRISPR/Cas9 methodology, will undoubtedly increase 
and democratize plant transformation events and will certainly contribute to the 
increase of genetically modified species for molecular pharming purposes.
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